ROCKWELL MEDICAL, INC.
RMTI evidence brief
What we can confirm
- Market Cap:
- $34.8M
What it means
What to watch
Prepared research question
What matters most for RMTI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RMTI
Rockwell Medical, Inc. (RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide [sec_mda · as of 2026-08-13].
Key risk: Capital raising uncertainty
Market Cap
$34.8M
Cash Runway
—
Lead Asset
—
Next Catalyst
—
Financial data as of Jun 30, 2026.
Rockwell Medical, Inc. (RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide [sec_mda · as of 2026-08-13].
- Rockwell Medical is a supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients [sec_mda · as of 2026-08-13].
- As of June 30, 2026, the company had approximately $24.8 million of cash, cash equivalents and investments available-for-sale, and net working capital of $25.2 million [sec_mda · as of 2026-08-13].
- For the six months ended June 30, 2026, interest expense was partially offset by $0.3 million of realized gains on available-for-sale investments [sec_mda · as of 2026-08-13].
- The company's long-term funding ability is highly dependent on executing growth strategy, achieving sustained profitability, and developing new products [sec_mda · as of 2026-08-13].
- Rockwell may raise capital through its $13.1 million remaining ATM facility or other financings, but there is no assurance of securing additional capital on acceptable terms [sec_mda · as of 2026-08-13].
What works
- Rockwell has a clear market position as a supplier of hemodialysis concentrates for a large and established end-stage kidney disease treatment market [sec_mda · as of 2026-08-13].
- Management believes the company has sufficient funds to meet operating requirements for at least the next twelve months from the date of the filing [sec_mda · as of 2026-08-13].
- The company has access to an ATM facility with $13.1 million remaining availability for potential capital raises [sec_mda · as of 2026-08-13].
What to weigh
- The company's long-term funding is highly dependent on executing growth strategy and achieving sustained profitability, both subject to significant risks and uncertainties [sec_mda · as of 2026-08-13].
- There is no assurance that Rockwell will be able to secure additional capital or funding on acceptable terms, or at all [sec_mda · as of 2026-08-13].
- If unable to execute its business plan and raise required capital, the company may be forced to curtail activities and ultimately cease operations [sec_mda · as of 2026-03-26].
From the filings
Quoted directly from source documents.
Rockwell Medical is a healthcare company that develops, manufactures, commercializes, and distributes hemodialysis products.
“Rockwell is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide.”
SEC MD&A · August 13, 2026
As of June 30, 2026, the company had approximately $24.8 million of cash, cash equivalents and investments available-for-sale.
“As of June 30, 2026, we had approximately $24.8 million of cash, cash equivalents and investments available-for-sale, and net working capital of $25.2 million.”
SEC MD&A · August 13, 2026
The company's long-term funding is highly dependent on executing growth strategy, achieving sustained profitability, and developing new products.
“We believe our ability to fund our activities in the long term will be highly dependent upon (i) our ability to execute on the growth strategy of our hemodialysis concentrates business and maintain sales with existing customers, (ii) our ability to achieve sustained profitability and (iii) our ability to identify, develop, in-license, or acquire new products in developing our product portfolio.”
SEC MD&A · August 13, 2026
If unable to execute business plan and raise capital, the company may cease operations.
“If we are unsuccessful in executing our business plan and we are unable to raise the required capital, we may be forced to curtail all of our activities and, ultimately, cease operations.”
SEC MD&A · March 26, 2026
Risks & what to watch (3)›
Key risks
- Capital raising uncertainty — No assurance of securing additional capital on acceptable terms; may lead to dilution or unfavorable terms [sec_mda · as of 2026-08-13].
- Dependence on growth execution — Long-term funding highly dependent on executing growth strategy and achieving sustained profitability [sec_mda · as of 2026-08-13].
- Potential cessation of operations — If unable to execute business plan and raise capital, company may be forced to curtail activities and cease operations [sec_mda · as of 2026-03-26].
What to watch
- Ability to execute growth strategy for hemodialysis concentrates business and maintain sales with existing customers [sec_mda · as of 2026-08-13].
- Progress in achieving sustained profitability and positive cash flow [sec_mda · as of 2026-08-13].
- Any capital raises through the ATM facility or other financings, and the terms obtained [sec_mda · as of 2026-08-13].
- Development, in-licensing, or acquisition of new products to expand the product portfolio [sec_mda · as of 2026-08-13].
Sources: SEC filings · SEC MD&A · Generated October 8, 2026 · How we verify sources →
Run ROCKWELL MEDICAL, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available ROCKWELL MEDICAL, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Financials
Short Interest
as of May 22, 2026- % of float
- 1.0%
- Days to cover
- 2.0
- Shares short
- 387,448
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RMTI short interestGovernance
Frequently asked questions
What is the AI investment thesis for ROCKWELL MEDICAL, INC.?
Rockwell Medical, Inc. (RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide [sec_mda · as of 2026-08-13].
Who is the CEO of ROCKWELL MEDICAL, INC.?
Dr. Mark Strobeck Ph.D. is the chief executive officer of ROCKWELL MEDICAL, INC. (RMTI).
Where is ROCKWELL MEDICAL, INC. headquartered?
ROCKWELL MEDICAL, INC. (RMTI) is headquartered in Wixom, MI, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.